{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T21:57:26Z","timestamp":1768773446814,"version":"3.49.0"},"reference-count":45,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T00:00:00Z","timestamp":1585785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Szu-Zuan Research Foundation of Internal Medicine","award":["No. 109009"],"award-info":[{"award-number":["No. 109009"]}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V108C-064"],"award-info":[{"award-number":["V108C-064"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background: Portal hypertension is characterized by exaggerated activation of the renin-angiotensin-aldosterone axis. Natriuretic peptide system plays a counter-regulatory role, which is modulated by neprilysin. LCZ696 (sacubitril\/valsartan) is a dual angiotensin receptor and neprilysin inhibitor. This study evaluated the effect of LCZ696 on portal hypertensive rats. Methods: Portal hypertension was induced by partial portal vein ligation (PVL) in rats. LCZ696, valsartan (angiotensin receptor blocker), or normal saline (control) was administered in PVL rats for 10 days. Then, hemodynamic and biochemistry data were obtained. The hepatic histology and protein expressions were surveyed. On the parallel groups, the portal-systemic shunting degrees were determined. Results: LCZ696 and valsartan reduced mean arterial pressure and systemic vascular resistance. LCZ696, but not valsartan, reduced portal pressure in portal hypertensive rats (control vs. valsartan vs. LCZ696: 15.4 \u00b1 1.6 vs. 14.0 \u00b1 2.3 vs. 12.0 \u00b1 2.0 mmHg, control vs. LCZ696: P &lt; 0.05). LCZ696 and valsartan improved liver biochemistry data and reduced intrahepatic Cluster of Differentiation 68 (CD68)-stained macrophages infiltration. Hepatic endothelin-1 (ET-1) protein expression was downregulated by LCZ696. The portal-systemic shunting was not affected by LCZ696 and valsartan. Conclusion: LCZ696 and valsartan reduced mean arterial pressure through peripheral vasodilation. Furthermore, LCZ696 significantly reduced portal pressure in PVL rats via hepatic ET-1 downregulation.<\/jats:p>","DOI":"10.3390\/pharmaceutics12040320","type":"journal-article","created":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T13:39:34Z","timestamp":1585834774000},"page":"320","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Dual Angiotensin Receptor and Neprilysin Inhibitor Ameliorates Portal Hypertension in Portal Hypertensive Rats"],"prefix":"10.3390","volume":"12","author":[{"given":"Shao-Jung","family":"Hsu","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan"},{"name":"Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei 11217, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Chun","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan"},{"name":"Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei 11217, Taiwan"},{"name":"Division of General Medicine, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiao-Lin","family":"Chuang","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei 11217, Taiwan"},{"name":"Division of General Medicine, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5526-5389","authenticated-orcid":false,"given":"Ching-Chih","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan"},{"name":"Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei 11217, Taiwan"},{"name":"Division of General Medicine, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Chih","family":"Hou","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan"},{"name":"Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei 11217, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fa-Yauh","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan"},{"name":"Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei 11217, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shou-Dong","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan"},{"name":"Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei 11217, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,4,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1445-5994.2004.00739.x","article-title":"Modern management of portal hypertension","volume":"35","author":"Lubel","year":"2005","journal-title":"Intern. Med. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/j.1440-1746.2008.05461.x","article-title":"Liver disease and the renin-Angiotensin system: Recent discoveries and clinical implications","volume":"23","author":"Lubel","year":"2008","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jhep.2010.03.013","article-title":"Renin-Angiotensin-Aldosterone inhibitors in the reduction of portal pressure: A systematic review and meta-Analysis","volume":"53","author":"Tandon","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1365-2362.2011.02611.x","article-title":"Aliskiren reduces portal pressure in portal hypertensive rats","volume":"42","author":"Chang","year":"2012","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nrneph.2011.29","article-title":"Limitations of angiotensin inhibition","volume":"7","author":"Nobakht","year":"2011","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_6","first-page":"321","article-title":"Natriuretic peptides","volume":"30","author":"Levin","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1161\/01.CIR.97.23.2323","article-title":"Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo","volume":"97","author":"Ferro","year":"1998","journal-title":"Circulation"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"PARADIGM-HF Investigators and Committees. Angiotensin-Neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.15420\/cfr.2016:1:1","article-title":"The Mechanism of Action of LCZ696","volume":"2","author":"Menendez","year":"2016","journal-title":"Card Fail Rev."},{"key":"ref_10","first-page":"728","article-title":"Pharmacokinetics and safety of sacubitril\/valsartan (LCZ696) in patients with mild and moderate hepatic impairment","volume":"55","author":"Kulmatycki","year":"2017","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1089-3261(05)70185-9","article-title":"Cellular and molecular basis of portal hypertension","volume":"5","author":"Shah","year":"2001","journal-title":"Clin. Liver. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jhep.2005.04.017","article-title":"Neutral endopeptidase (EC 3.4.24.11) in cirrhotic liver: A new target to treat portal hypertension?","volume":"43","author":"Aragno","year":"2005","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1034\/j.1600-0676.2000.020001088.x","article-title":"Haemodynamic responses to a ring-Deleted analogue of atrial natriuretic peptide in rats with cirrhosis","volume":"20","author":"Moreau","year":"2000","journal-title":"Liver"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/0016-5085(92)90179-3","article-title":"Vasodilatation and sodium retention in prehepatic portal hypertension","volume":"102","author":"Albillos","year":"1992","journal-title":"Gastroenterology"},{"key":"ref_15","first-page":"G980","article-title":"Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state","volume":"290","author":"Abraldes","year":"2006","journal-title":"Am. J. Physiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jhep.2003.10.010","article-title":"Chronic inhibition of nitric oxide increases the collateral vascular responsiveness to vasopressin in portal hypertensive rats","volume":"40","author":"Huang","year":"2004","journal-title":"J. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1164\/rccm.201008-1303OC","article-title":"A central role for CD68 (+) macrophages in hepatopulmonary syndrome. Reversal by macrophage depletion","volume":"183","author":"Thenappan","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jash.2017.04.012","article-title":"Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: Sacubitril\/valsartan","volume":"11","author":"Chrysant","year":"2017","journal-title":"J. Am. Soc. Hypertens."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/ki.2015.107","article-title":"Optimum AT1 receptor-Neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats","volume":"88","author":"Roksnoer","year":"2015","journal-title":"Kidney Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1136\/heartjnl-2017-311295","article-title":"Sacubitril\/valsartan: Beyond natriuretic peptides","volume":"103","author":"Singh","year":"2017","journal-title":"Heart"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejphar.2018.02.007","article-title":"Neprilysin inhibition and endothelin-1 elevation: Focus on the kidney","volume":"824","author":"Roksnoer","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e005819","DOI":"10.1161\/CIRCHEARTFAILURE.119.005819","article-title":"Treatment of Pulmonary Hypertension with Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril\/Valsartan","volume":"12","author":"Clements","year":"2019","journal-title":"Circ. Heart Fail."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/ajh\/hpv015","article-title":"LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone","volume":"28","author":"Kusaka","year":"2015","journal-title":"Am. J. Hypertens."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Seki, T., Goto, K., Kansui, Y., Ohtsubo, T., Matsumura, K., and Kitazono, T. (2017). Angiotensin II Receptor-Neprilysin Inhibitor Sacubitril\/Valsartan Improves Endothelial Dysfunction in Spontaneously Hypertensive Rats. J. Am. Heart Assoc., 6.","DOI":"10.1161\/JAHA.117.006617"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S0168-8278(98)80352-8","article-title":"The effect of endothelin and its antagonist Bosentan on hemodynamics and microvascular exchange in cirrhotic rat liver","volume":"28","author":"Reichen","year":"1998","journal-title":"J. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1042\/CS20090601","article-title":"Administration of a low dose of sildenafil for 1 week decreases intrahepatic resistance in rats with biliary cirrhosis: The role of NO bioavailability","volume":"119","author":"Lee","year":"2010","journal-title":"Clin. Sci. (Lond.)"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6208","DOI":"10.3748\/wjg.14.6208","article-title":"Sildenafil does not influence hepatic venous pressure gradient in patients with cirrhosis","volume":"14","author":"Clemmesen","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/labinvest.2016.116","article-title":"CD68\/macrosialin: Not just a histochemical marker","volume":"97","author":"Chistiakov","year":"2017","journal-title":"Lab. Investig."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Liczek, M., Panek, I., Damia\u0144ski, P., J\u0119cze\u0144, O., Ja\u017awiec, J., Kuna, P., and Panek, M. (2018). Neprilysin inhibitors as a new approach in the treatment of right heart failure in the course of chronic obstructive pulmonary disease. Adv. Respir. Med.","DOI":"10.5603\/ARM.a2018.0028"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Theuer, J., Dechend, R., Muller, D.N., Park, J.K., Fiebeler, A., Barta, P., Ganten, D., Haller, H., Dietz, R., and Luft, F.C. (2002). Angiotensin II induced inflammation in the kidney and in the heart of double transgenic rats. BMC Cardiovasc. Disord., 2.","DOI":"10.1186\/1471-2261-2-3"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11596-008-0306-3","article-title":"Effect of ARB on expression of CD68 and MCP-1 in adipose tissue of rats on long-Term high fat diet","volume":"28","author":"Guo","year":"2008","journal-title":"J. Huazhong. Univ. Sci. Technol. Med. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1507\/endocrj.K07-004","article-title":"Angiotensin II type 1 receptor blocker reduces monocyte adhesion to endothelial cells in spontaneously hypertensive rats","volume":"54","author":"Ikeda","year":"2007","journal-title":"Endocr. J."},{"key":"ref_33","first-page":"5473","article-title":"LCZ696 (Sacubitril\/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD","volume":"9","author":"Jing","year":"2017","journal-title":"Am. J. Transl. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12933-019-0847-8","article-title":"The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat","volume":"18","author":"Habibi","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/HJH.0000000000002326","article-title":"Angiotensin-Neprilysin inhibition confers renoprotection in rats with diabetes and hypertension by limiting podocyte injury","volume":"38","author":"Uijl","year":"2020","journal-title":"J. Hypertens."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"381","DOI":"10.4318\/tjg.2010.0124","article-title":"Relationship of increased serum brain natriuretic peptide levels with hepatic failure, portal hypertension and treatment in patients with cirrhosis","volume":"21","author":"Yilmaz","year":"2010","journal-title":"Turk. J. Gastroenterol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.clinbiochem.2012.01.009","article-title":"Serum NT-pro CNP concentrations are elevated in patients with chronic liver diseases and associated with complications and unfavorable prognosis of cirrhosis","volume":"45","author":"Koch","year":"2012","journal-title":"Clin. Biochem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/hep.1840150424","article-title":"Atrial natriuretic peptide in portal vein-Ligated rats: Alterations in cardiac production, plasma level and glomerular receptor density and affinity","volume":"15","author":"Jonas","year":"1992","journal-title":"Hepatology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/imj.12590","article-title":"Portal hypertension: Pathophysiology, diagnosis and management","volume":"45","author":"Bloom","year":"2015","journal-title":"Intern. Med. J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1089\/ten.tea.2008.0414","article-title":"B-Type natriuretic peptide enhances vasculogenesis by promoting number and functional properties of early endothelial progenitor cells","volume":"15","author":"Shmilovich","year":"2009","journal-title":"Tissue Eng. Part A"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1161\/01.HYP.27.3.811","article-title":"Vascular endothelial growth factor suppresses C-type natriuretic peptide secretion","volume":"27","author":"Doi","year":"1996","journal-title":"Hypertension"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/1440-1681.12251","article-title":"Natriuretic peptide clearance receptor ligand (C-ANP4-23) attenuates angiogenesis in a murine sponge implant model","volume":"41","author":"Almeida","year":"2014","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.2353\/ajpath.2009.090439","article-title":"Atrial natriuretic peptide reduces vascular leakage and choroidal neovascularization","volume":"175","author":"Zandi","year":"2009","journal-title":"Am. J. Pathol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0008-6363(02)00843-X","article-title":"VEGF-Mediated angiogenesis is impaired by angiotensin type 1 receptor blockade in cardiomyopathic hamster hearts","volume":"58","author":"Shimizu","year":"2003","journal-title":"Cardiovasc. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/hepr.12008","article-title":"Dual blockade of angiotensin-II and aldosterone suppresses the progression of a non-Diabetic rat model of steatohepatitis","volume":"43","author":"Noguchi","year":"2013","journal-title":"Hepatol. Res."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/12\/4\/320\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:14:44Z","timestamp":1760174084000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/12\/4\/320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,2]]},"references-count":45,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4]]}},"alternative-id":["pharmaceutics12040320"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics12040320","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,2]]}}}